» Articles » PMID: 37665162

Genetic and Structural Analyses Reveal the Low Potential of the SARS-CoV-2 EG.5 Variant

Overview
Journal J Med Virol
Specialty Microbiology
Date 2023 Sep 4
PMID 37665162
Authors
Affiliations
Soon will be listed here.
Abstract

The severe acute respiratory syndrome coronavirus 2 EG.5 lineage is the latest variant under monitoring, and it is generating significant concern due to its recent upward trend in prevalence. Our aim was to gain insights into this emerging lineage and offer insights into its actual level of threat. Both genetic and structural data indicate that this novel variant presently lacks substantial evidence of having a high capacity for widespread transmission. Their viral population sizes expanded following a very mild curve and peaked several months after the earliest detected sample. Currently, neither the viral population size of EG.5 nor that of its first descendant is increasing. The genetic variability appear to be flattened, as evidenced by its relatively modest evolutionary rate (9.05 × 10 subs/site/year). As has been observed with numerous prior variants, attributes that might theoretically provide advantages seem to stem from genetic drift, enabling the virus to continually adjust to its host, albeit without a clear association with enhanced dangerousness. These findings further underscore the necessity for ongoing genome-based monitoring, ensuring preparedness and a well-documented understanding of the unfolding situation.

Citing Articles

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.

Guo H, Ha S, Botten J, Xu K, Zhang N, An Z Viruses. 2024; 16(5).

PMID: 38793580 PMC: 11125895. DOI: 10.3390/v16050697.


Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.

Sil D, Gautam S, Saxena S, Joshi S, Kumar D, Mehta A Curr Drug Targets. 2024; 25(8):517-525.

PMID: 38726782 DOI: 10.2174/0113894501296586240430061915.


On the SARS-CoV-2 Variants.

Scarpa F, Branda F, Petrosillo N, Ciccozzi M Infect Dis Rep. 2024; 16(2):289-297.

PMID: 38667750 PMC: 11050187. DOI: 10.3390/idr16020024.


Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.

Xue S, Han Y, Wu F, Wang Q Protein Cell. 2024; 15(6):403-418.

PMID: 38442025 PMC: 11131022. DOI: 10.1093/procel/pwae007.


Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial.

Tang J, Xu Q, Zhu C, Xuan K, Li T, Li Q Vaccines (Basel). 2024; 12(2).

PMID: 38400158 PMC: 10893468. DOI: 10.3390/vaccines12020175.